Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jared Gollob

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Expert Opinion on Pharmacotherapy|November 30, 2018
An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathyViolaine Planté-Bordeneuve, Hollis Lin, Jared Gollob, et al.
Progress in Transplantation (Aliso Viejo, Calif.)|June 7, 2019
Evaluating Prognostic Factors for Liver Transplantation Among United States Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis Using National Registry DataDanielle Brandman, Hollis Lin, Anastasia McManus, et al.
The Journal of Investigative Dermatology|July 31, 2024
IRAK4 Is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory BiomarkersAlice McDonald, Rahul Karnik, Veronica Campbell, et al.
Silence|July 10, 2010
A status report on RNAi therapeuticsAkshay K Vaishnaw, Jared Gollob, Christina Gamba-Vitalo, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 28, 2010
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virusJohn DeVincenzo, Robert Lambkin-Williams, Tom Wilkinson, et al.
BMC Neurology|September 13, 2017
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathyDavid Adams, Ole B Suhr, Peter J Dyck, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA ConjugateTracy S Zimmermann, Verena Karsten, Amy Chan, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 28, 2020
DISCOVERY: prevalence of transthyretin (<i>TTR</i>) mutations in a US-centric patient population suspected of having cardiac amyloidosisOla Akinboboye, Keyur Shah, Alberta L Warner, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeuticsMichael B Atkins, David Carbone, George Coukos, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|October 11, 2015
Serial scanning with technetium pyrophosphate (<sup>99m</sup>Tc-PYP) in advanced ATTR cardiac amyloidosisAdam Castaño, Albert DeLuca, Richard Weinberg, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Expert Opinion on Pharmacotherapy|November 30, 2018
An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathyViolaine Planté-Bordeneuve, Hollis Lin, Jared Gollob, et al.
Progress in Transplantation (Aliso Viejo, Calif.)|June 7, 2019
Evaluating Prognostic Factors for Liver Transplantation Among United States Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis Using National Registry DataDanielle Brandman, Hollis Lin, Anastasia McManus, et al.
The Journal of Investigative Dermatology|July 31, 2024
IRAK4 Is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory BiomarkersAlice McDonald, Rahul Karnik, Veronica Campbell, et al.
Silence|July 10, 2010
A status report on RNAi therapeuticsAkshay K Vaishnaw, Jared Gollob, Christina Gamba-Vitalo, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 28, 2010
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virusJohn DeVincenzo, Robert Lambkin-Williams, Tom Wilkinson, et al.
BMC Neurology|September 13, 2017
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathyDavid Adams, Ole B Suhr, Peter J Dyck, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA ConjugateTracy S Zimmermann, Verena Karsten, Amy Chan, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 28, 2020
DISCOVERY: prevalence of transthyretin (<i>TTR</i>) mutations in a US-centric patient population suspected of having cardiac amyloidosisOla Akinboboye, Keyur Shah, Alberta L Warner, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeuticsMichael B Atkins, David Carbone, George Coukos, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|October 11, 2015
Serial scanning with technetium pyrophosphate (<sup>99m</sup>Tc-PYP) in advanced ATTR cardiac amyloidosisAdam Castaño, Albert DeLuca, Richard Weinberg, et al.
Pageof 2